Assessing the significance of BRCA1 and BRCA2 mutations in pancreatic cancer

Journal of Clinical Oncology

Volumn 33, Issue 28, 2015, Pages 3080-3081

  Carnevale, Julia ^a   Ashworth, Alan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; BRCA1 PROTEIN; BRCA2 PROTEIN;

CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE PREDISPOSITION; DNA DAMAGE; DNA REPAIR; EDITORIAL; FAMILIAL CANCER; GENE MUTATION; GENE SEQUENCE; GENETIC SCREENING; HUMAN; PANCREAS CANCER; PREVALENCE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; FEMALE; GENETICS; GERMLINE MUTATION; MALE; PANCREAS CARCINOMA; PANCREAS TUMOR;

BRCA1 PROTEIN; BRCA2 PROTEIN; CARCINOMA, PANCREATIC DUCTAL; FEMALE; GERM-LINE MUTATION; HUMANS; MALE; PANCREATIC NEOPLASMS;

EID: 84939436494     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.61.6961     Document Type: Editorial

References (14)

1. SEER Program: SEER Cancer Statistics Review 1975-2011. http://seer.cancer.gov/csr/1975-2011
2. Couch FJ, Johnson MR, Rabe KG, et al: The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev 16: 342-346, 2007
3. Hahn SA, Greenhalf B, Ellis I, et al: BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 95: 214-221, 2003
4. Murphy KM, Brune KA, Griffin C, et al: Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: Deleterious BRCA2 mutations in 17%. Cancer Res 62: 3789-3793, 2002
5. Lord CJ, Ashworth A: The DNA damage response and cancer therapy. Nature 481: 287-294, 2012
6. Holter S, Borgida A, Dodd A, et al: Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma. J Clin Oncol 33: 3124-3129, 2015
7. Jones S, Hruban RH, Kamiyama M, et al: Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 324: 217, 2009
8. Slater EP, Langer P, Niemczyk E, et al: PALB2 mutations in European familial pancreatic cancer families. Clin Genet 78: 490-494, 2010
9. Golan T, Kanji ZS, Epelbaum R, et al: Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer 111: 1132-1138, 2014
10. Lowery MA, Kelsen DP, Stadler ZK, et al: An emerging entity: Pancreatic adenocarcinoma associated with a known BRCA mutation-Clinical descriptors, treatment implications, and future directions. Oncologist 16: 1397-1402, 2011
11. Kaufman B, Shapira-Frommer R, Schmutzler RK, et al: Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 33: 244-250, 2015
12. Waddell N, Pajic M, Patch AM, et al: Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518: 495-501, 2015
13. Alexandrov LB, Nik-Zainal S, Wedge DC, et al: Signatures of mutational processes in human cancer. Nature 500: 415-421, 2013
14. Turner N, Tutt A, Ashworth A: Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 4: 814-819, 2004